AbstractWe have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an N-terminal fusion with an engineered protein domain from the Geobacillus stearothermophilus pyruvate dehydrogenase subunit E2. Mice immunized with the Gag(p17)-E2 60-mer scaffold particles mounted a strong and sustained antibody response. Antibodies directed to Gag(p17) were boosted significantly with additional immunizations, while anti-E2 responses reached a plateau. The isotype of the induced antibodies was biased towards IgG1, and the E2-primed CD4+ T cells did not secrete IFNγ. Using transgenic mouse model systems, we demonstrated that CD8+ T cells primed with E2 particles were able to exert lytic activity and produce IFNγ. These results...
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regim...
AbstractSimian immunodeficiency virus (SIV) is a robust pathogen used in non-human primates to model...
HIV-1 candidate vaccines expressing an artificial polyprotein comprising Gag, Pol and Nef (GPN) and ...
AbstractWe have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an ...
To obtain proof of concept for HIV vaccines, we generated recombinant multimeric particles displayin...
Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox...
AbstractVenezuelan equine encephalitis virus replicon particles (VRP) were engineered to express dif...
Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies compr...
Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies compr...
AbstractVery recently, we demonstrated that the replacement of the human immunodeficiency virus type...
AbstractWe have generated a codon-optimized hGagp17p24–Polp51 plasmid DNA expressing the human immun...
Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine im...
The development of an effective Human Immunodeficiency Virus (HIV) vaccine that is able to stimulate...
Virus-like particles (VLPs) constitute a promising approach for recombinant vaccine development. The...
Vaccination with exogenous antigens such as recombinant viral proteins, immunodeficiency virus-deriv...
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regim...
AbstractSimian immunodeficiency virus (SIV) is a robust pathogen used in non-human primates to model...
HIV-1 candidate vaccines expressing an artificial polyprotein comprising Gag, Pol and Nef (GPN) and ...
AbstractWe have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an ...
To obtain proof of concept for HIV vaccines, we generated recombinant multimeric particles displayin...
Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox...
AbstractVenezuelan equine encephalitis virus replicon particles (VRP) were engineered to express dif...
Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies compr...
Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies compr...
AbstractVery recently, we demonstrated that the replacement of the human immunodeficiency virus type...
AbstractWe have generated a codon-optimized hGagp17p24–Polp51 plasmid DNA expressing the human immun...
Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine im...
The development of an effective Human Immunodeficiency Virus (HIV) vaccine that is able to stimulate...
Virus-like particles (VLPs) constitute a promising approach for recombinant vaccine development. The...
Vaccination with exogenous antigens such as recombinant viral proteins, immunodeficiency virus-deriv...
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regim...
AbstractSimian immunodeficiency virus (SIV) is a robust pathogen used in non-human primates to model...
HIV-1 candidate vaccines expressing an artificial polyprotein comprising Gag, Pol and Nef (GPN) and ...